



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/20	A2	(11) International Publication Number: WO 97/48384 (43) International Publication Date: 24 December 1997 (24.12.97)
<p>(21) International Application Number: PCT/EP97/03066</p> <p>(22) International Filing Date: 10 June 1997 (10.06.97)</p> <p>(30) Priority Data: 60/020,274 17 June 1996 (17.06.96) US</p> <p>(60) Parent Application or Grant (63) Related by Continuation US 60/020,274 (CON) Filed on 17 June 1996 (17.06.96)</p> <p>(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): POSAGE, Gary, W. [US/US]; Janssen Research Technology Center, 655 Phoenix Drive, Ann Arbor, MI 48108 (US).</p>	<p>(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
<p>(54) Title: MARKING RAPIDLY DISINTEGRATING DOSAGE FORMS</p>		
<p>(57) Abstract</p> <p>The present invention relates to a method of marking the surface of solid rapidly disintegrating dosage forms using a non-contact marking technique such as laser imprinting and ink-jet printing.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

MARKING RAPIDLY DISINTEGRATING DOSAGE FORMS

- 5 The present invention relates to a method of marking the surface of solid rapidly disintegrating dosage forms using a non-contact marking technique such as laser imprinting and ink-jet printing.

10 Solid rapidly disintegrating dosage forms loaded with a predetermined quantity of an active ingredient are known from GB-A-1,548,022 (US-4,305,502). These solid dosage forms comprise a porous network of a matrix material carrying an active ingredient, the matrix material consisting of a water-soluble or a water-dispersable carrier material. The solid dosage forms are prepared by freeze-drying or lyophilization of the solvent from a frozen solution or suspension of the matrix material and the active ingredient.

15 Various improvements for preparing dosage forms by lyophilization have been developed. GB-A-2,111,423 and US-4,371,516 disclose such methods of preparing solid dosage forms which are rapidly disintegrated by water and in which a network of matrix material carries a predetermined amount of an active ingredient, particularly a
20 pharmaceutical substance. Such dosage forms find many applications, particularly where it is desired to administer, dispense or otherwise utilise an active ingredient in predetermined unit quantities. For example, certain active ingredients which are used in solution or suspension form, but which are difficult or hazardous to transport or store in such form, may be converted into a solid form which can be added by the user to an
25 aqueous medium to produce the desired solution or dispersion containing a predetermined amount of the active ingredient. Further, the active ingredient may be a reagent which can be added to a known amount of aqueous liquid to produce a standardised liquid composition which then can be used, for example, in chemical analysis. Further, the active ingredient may be a diagnostic compound which has to be
30 added to a biological sample (e.g. blood, urine) and thus allows one to determine the amount of a particular constituent present in the sample. Preferably, however, the active ingredient is a drug substance for human or veterinary use. Rapidly dissolving solid drug dosage forms are particularly suitable for oral administration. When orally administered they generally disintegrate rapidly in the mouth (e.g. within one or two
35 seconds) and thus the dosage form is a particularly advantageous means for administering drugs to humans and animals. Such dosage forms can be used as alternatives to conventional tablets, pills or capsules, particularly for patients - humans and animals alike - who have difficulty in swallowing these conventional dosage forms.

US-4,642,903 teaches a procedure for preparing a freeze-dried foam dosage form using conventional lyophilization techniques which results in rapidly dissolving pharmaceutical dosage forms.

5

WO-93/23017 addresses a problem intrinsic to conventional lyophilization methods namely the lack of uniform porosity in the lyophilized product. Uniform porosity in a lyophilized product is critical for post-loading a placebo or unloaded dosage form with an active ingredient. WO-93/23017 concerns a method of producing a dosage form that will avoid cracking and meltback, has adequate strength, and porosity and exhibits a fast speed of dissolution.

10

Other methods for the preparation of solid dosage forms which rapidly disintegrate in the mouth, namely solid state dissolution techniques are disclosed in US-5,039,540, US-A-5,215,756, US-A-5,330,764, and US-5,298,261.

15

Solid dosage forms as provided by the prior art are used to deliver predetermined amounts of active ingredients. Since the administration of such products is associated with many risks, there is a need to bestow an identity on them. Such risks include, for example, errors in the administration of medicines by physicians, pharmacists or by the end-users, the patients. Several regulatory authorities have issued regulations requiring all solid oral dosage forms to bear a code identifying the product and the holder of the manufacturing authorisation.

20

Besides using distinct colours and dosage shapes, this problem can be solved satisfactorily in classic solid dosage forms such as compressed tablets and capsules, by imprinting. Typically, a mark or text is printed on the dosage form surface, e.g. a company logo or name, a product name, a trade mark, or a number indicating the amount of active ingredient in the dosage form. An alternative solution applicable to tablets consists of intagliating the surface thereof by a compression punching, incision or engraving procedure. The intagliations can be highlighted by filling with an optically anisotropic substance (e.g. EP-0,060,023 and EP-0,096,982), by dry filling with a material having a different colour (EP-0,088,556) or by wet filling with a material having a different colour (EP-0,501,553).

30

35

The use of distinct colours and dosage shapes clearly also applies to solid rapidly dissolving dosage forms comprising a non-compressed porous network of matrix forming materials. Thus far, however, no solutions have been offered for marking such

dosage forms with imprints or intagliations. The reduced mechanical strength, in particular the compressible nature of these dosage forms, as compared to conventional compressed tablets, has impeded the application of prior art printing and intagliating techniques thereto. Said techniques rely on physical contact and pressure between the dosage form and the printing mat or stamp to transfer the mark to the tablet.

Now, a method has been developed of marking the surface of solid rapidly disintegrating dosage forms comprising a non-compressed, porous network of matrix forming materials, in which the foregoing problem is solved by applying legible marks and / or characters to the surface of said solid rapidly disintegrating dosage forms using non-contact marking techniques.

The present invention provides two such non-contact marking methods, namely laser imprinting and ink-jet printing.

According to the first method a laser is used to etch marks and / or characters into the surface of the dosage form by vaporizing a shallow and narrow portion of the surface. In order for the marks and or characters to be legible it suffices that a shadow be created in the valley left by the impinging laser beam. Since laser beams typically have a very small beam divergence, typically in the order of a few milliradian, the breadth of the valley at the surface of the solid dosage form can be very narrow, indeed. Under these circumstances, even a very shallow valley will cast a visible shadow. Most importantly, since the solid rapidly dissolving dosage forms comprise a porous network of matrix forming materials, very little material has to be vaporized in order to attain the desired objective. This is of great practical value for several reasons. First, since the energy input required to vaporize solid material is proportional to the amount of said material, little energy will be needed in the vaporization process. In effect, this means that the individual dosage forms will have to be irradiated only very shortly, or conversely that a great many dosage forms can be etched per time unit. This feature of high-throughput is of prime importance in rendering the marking method industrially viable. Secondly, the amount of material removed from the solid dosage form, in particular the amount of active ingredient removed from it, is so small relative to the total amount of the dosage form as to be negligible. Finally, the method using a laser has the further advantage of not introducing any new materials into the dosage form, which is a distinct advantage in pharmaceutical applications.

A first mode of etching the marks and / or characters into the surface of the dosage form comprises passing the laser beam through a mask or stencil, preferably in metal, precut

with the desired information. The laser beam forms an image of the mask and is then directed onto the surface of the part of the solid dosage form to be marked. Suitable lasers are those which have been designed for industrial marking applications and which produce short, powerful pulses of light energy, preferably in the infrared range
5 ($\lambda = 1 \mu\text{m} - 1 \text{mm}$), e.g. carbon dioxide lasers ($\lambda = 10.6 \mu\text{m}$), helium-neon lasers ($\lambda = 3.39 \mu\text{m}$) and the like. Preferably the pulsed lasers are used at low pulse energy (a few Joules) and at high repetition rate (e.g. 20 Hz) in order to attain a high, industrially viable mark speed (e.g. 1200 marks/min).

10 An alternative comprises moving a solid dosage form past a plurality of pulsed laser beams arranged along a single line thus creating dot matrix patterns on the surface of the solid dosage form.

A third mode of etching the marks and / or characters into the surface of the dosage
15 form comprises scanning a laser beam over the surface of the dosage form using rapidly rotating, computer controlled mirrors. In this mode, a YAG (yttrium aluminum garnet) or continuous wave carbon dioxide laser is used preferably to etch the product code information on the surface of a solid dosage form.

20 The vaporized portion of the surface comprises degraded matrix forming materials which are advantageously removed by suction using art-known devices.

According to the second method an ink-jet printer can be used to print marks and / or characters onto the surface of the dosage form by dotting droplets of an ink onto said
25 surface. Prior art methods of ink-jet printing, according to the inventor's knowledge, thus far have been applied exclusively to the marking of articles that are substantially impermeable to the ink. Surprisingly, it has proven perfectly possible to extend the ink-jet printing technology to highly porous solid dosage forms.

30 The ink used to mark dosage forms must be suspended or dissolved in a liquid, volatile carrier such as water, alcohol, or mixtures thereof. Water based ink jet inks can contain from 70 to 90 % water depending on the nature of the ink. Because of the small droplet size, the solvent evaporates rapidly and does not affect the structure of the solid dosage form. The ink can be edible or non-edible depending on the final use of the dosage
35 form. In case the dosage form comprises a drug for human or veterinary use, obviously only pharmaceutically acceptable, edible inks can be used in the present method of marking the dosage form by means of an ink-jet printer.

The above methods are particularly useful when the dosage form is loaded with an active ingredient and is shaped as a tablet. The methods are more particularly suitable when the active ingredient is a drug substance for human or veterinary use and the solid rapidly disintegrating dosage form is a pharmaceutical tablet for oral administration.

5

The dosage form comprises a porous network of matrix forming materials :

- i) a water-soluble, hydratable gel or foam-forming material,
- ii) a rigidifying agent for the gel or foam-forming material, and optionally
- iii) one or more amino acids.

10

The solid dosage forms are prepared by lyophilization or by a solid state dissolution technique of a frozen mixture of a solvent with the matrix forming materials. These mixtures may be in a variety of forms such as solutions, suspensions, dispersions, emulsions, foams. Persons skilled in the art will recognize acceptable methods for preparing each of these.

15

Water is preferably employed as the solvent in the composition which is frozen and desolvated. An additional co-solvent (such as an alcohol) may also be used if it is desired to improve the solubility, dispersability or wettability of any of the ingredients of the composition.

20

Suitable water-soluble, hydratable gel or foam-forming materials include proteinaceous materials such as gelatin, gelatin A, gelatin B, fluid gelatin, modified fluid gelatin, gelatin derivatives, albumin, soy fiber protein, wheat and psyllium seed proteins, potato protein, papain; phospholipids such as coacervate egg lecithin, or lecithin; gums such as acacia, guar, agar, locust bean, xanthan and tragacanth gum ; polysaccharides such as alginates (polymannuronic acid), chitosan, carrageenans, dextrans, dextrans, maltrins (maltodextrins), pectins (polygalacturonic acid), microcrystalline cellulose, corn syrup solids, konjac flour, rice flour, wheat gluten ; synthetic polymers such as polyvinylpyrrolidone, sodium carboxymethylcellulose, sodium starch glycolate, hydroxyethylcellulose; and polypeptide/protein or poly-saccharide complexes such as gelatin-acacia complexes, each singly or in combination.

25

30

Suitable rigidifying agents include monosaccharides, linear and cyclic oligosaccharides and polysaccharides, e.g. mannitol, xylitol, sorbitol, dextrose, fructose, sucrose, lactose, maltose, galactose, trehalose ; cyclic sugars such as cyclodextrins e.g. beta-cyclodextrin and 2-hydroxypropyl-beta-cyclodextrin ; dextran, dextrin ; and further include inorganic substances such as sodium phosphate, sodium chloride, magnesium

35

aluminum silicates, magnesium trisilicate, natural clays, or a combination thereof. The preferred rigidifying agent is mannitol.

Suitable amino acids have from 2 to 12 carbon atoms, e.g. glycine, L-alanine,
5 L-aspartic acid, L-glutamic acid, L-hydroxyproline, L-isoleucine, L-leucine,
L-phenylalanine, or a combination thereof. Glycine is the preferred amino acid.
Dosage forms containing glycine as one of the matrix forming components have several
advantages : quick dissolution and disintegration in aqueous media, pleasant taste and
mouthfeel, nutritional value, low caloric content and noncariogenicity. Of particular
10 importance is the fact that these dosage forms can be produced with minimal cracking
or meltback and that they have uniform porosity and adequate strength of handling, i.e.
resistance to disintegration or crumbling under normal manufacturing and handling
conditions. These latter properties contribute to the feasibility of the post-loading
processes whereby active ingredients are loaded onto placebo or unloaded dosage
15 forms.

Preferred matrix forming agents include pharmaceutical grade gelatins, pectins
(nonhydrolyzed, partially hydrolyzed or hydrolyzed), glycine and mannitol. A
particularly preferred combination of matrix forming agents comprises gelatin, glycine
20 and mannitol.

The percentages and ratios mentioned in the following paragraphs are all by weight.

The solution or dispersion of materials for preparing the matrix can contain from 0.1 %
25 to 15 % by weight of gel or foam forming material, in particular from 1 % to 5 % more
in particular from 1.2 % to 3 %. It can further contain from 0.5 % to 10 %, in particular
from 0.8 % to 2.5 % by weight of amino acid and from 0.5 % to 10 %, in particular
from 1 % to 4 % of rigidifying agent, the remainder being solvent and secondary
components as mentioned hereinafter.

30 The ratios between these materials may vary within certain ranges. In particular the
weight by weight ratio of the total amount of amino acids to that of the water-soluble,
hydratable gel or foam-forming material is from 1 : 1 to 1 : 3. A preferred ratio is
1.5 : 1. The weight by weight ratio of the amount of the water-soluble, hydratable gel
35 or foam-forming material to that of the rigidifying agent is from 2 : 1 to 1 : 2. A
preferred ratio is 1.5 : 2.

Typically, the weight by weight ratio of the total amount of non-solvent components to that of the water in the aqueous composition is in the range of about 1 : 9 to 1 : 33, in particular from about 1 : 13 to 1 : 30, for example about 1 : 20.

- 5 Solid rapidly dissolving dosage forms find many applications, particularly where it is desired to administer, dispense or otherwise utilise an active ingredient in predetermined unit quantities. The active ingredient in particular is a drug substance for human or veterinary use.
- 10 The active ingredient used in the solid rapidly dissolving dosage form may be present in a coated form. For example, it may be present in particulate form and the particles of the active ingredient may be coated with an appropriate coating agent so as to protect it from process diluents, the aqueous environment of the suspension or of the oral or other mucosal cavity, or other environmental conditions that would dissolve or deteriorate
- 15 said active ingredient. These coating materials may be selected from natural or synthetic polymers that are either hydrophilic or hydrophobic in nature or other hydrophobic materials such as fatty acid, glycerides, triglycerides and mixtures thereof. In this way, the taste of the active or bioactive agent may be masked, while at the same time permitting the solid dosage form to dissolve rapidly upon contact with physio-
- 20 logical diluents. Examples of bitter active ingredients that may be coated in accordance with the present invention include acetaminophen, ibuprofen, chlorpheniramine maleate, pseudo-ephedrine, dextromethorphan, cisapride, domperidone, risperidone. Pharmaceutical applications comprise dosage forms having mucoadhesive properties or designed to deliver a drug at a controlled rate; dosing units designed to deliver drugs in
- 25 the eye, in vaginal, rectal and other body orifices; solid dosage forms designed to replace liquid formulations; dry medicated preparations for topical application after resolution (reconstitution); preparation of medicated units or sheets for topical application; preparation of more palatable dosage forms of drugs that exhibit disagreeable organoleptic properties; dosage forms for oral delivery of drugs to persons
- 30 who have difficulty swallowing tablets or capsules.

Secondary components such as nutrients, vitamins, other active ingredients, sweeteners, flavouring agents, colouring agents, surfactants, preservatives, antioxidants, viscosity enhancers, minerals, diagnostics, fertilizers and insecticides may also be incorporated in

35 the formulation of the dosage form.

The solution or suspension of which the dosage forms are made may further contain the secondary components mentioned before. Xanthan gum or polyacrylic acid polymers

and salts thereof (also referred to as carbomers or carboxyvinyl polymers, e.g. Carbopol™) may be added in order to increase viscosity, or to keep the components of the mixture in suspension.

- 5 The aqueous compositions may be frozen by any conventional cooling process. For example, the mixture may be frozen by dispensing it into preformed molds corresponding to the size and shape of the desired dosage form and subsequently cooling such molds on refrigerated shelves or in refrigerated chambers. Alternatively, the molds containing the mixture may be passed through a stream of cold gas or vapor,
10 such as liquid nitrogen in a freezing tunnel. In a preferred method of freezing, the composition is passed through a freezing tunnel into which liquid nitrogen is injected, the liquid nitrogen being vaporised and the resulting cold gaseous nitrogen being passed over the composition. Another method for freezing the mixtures in the molds is to surround the molds in dry ice until the mixture has frozen.

- 15 The best-known process of removing solvents from frozen solutions or dispersions is lyophilization which involves desolvation of the mixture by sublimation of the solvent under a vacuum. If desired, the frozen compositions may be stored in a cold store before the sublimation process is carried out. The sublimation may be carried out in a
20 freeze drier by subjecting the frozen composition in the mold to reduced pressure and, if desired, controlled application of heat to aid the sublimation. The pressure can be below 4 mmHg (533 Pa), e.g. below 0.3 mmHg (40 Pa), for example 0.1 to 0.2 mmHg (13.3 to 26.6 Pa) or even below 0.05 mmHg (6.7 Pa). The initial temperature in the freeze drier may be, for example, as high as 60°C and this temperature can be reduced
25 (e.g. to 40°C) as the temperature of the frozen composition increases. Various methods and improvements are described in the references cited at the very beginning of the specification. The frozen compositions also may be removed from the mold prior to lyophilization.

- 30 The dosage forms can also be prepared by a solid-state dissolution method of removing solid solvent from solidified samples. In this less conventional method, one or more delivery matrix forming agents are dissolved or dispersed in a first solvent, frozen and subsequently contacted with a second solvent at a temperature at or higher than the solidification point of the second solvent and at a temperature at or lower than the
35 solidification point of the first solvent. The first solvent in the solidified state is substantially miscible with the second solvent, while the matrix forming agent(s) are substantially insoluble in the second solvent. The first solvent is thereby substantially

removed from the solidified matrix yielding a solid matrix substantially free of the first solvent. Typically, the first solvent is water and the second ethanol.

- The mold can be, for example a depression in a metal plate (e.g. an aluminium plate).
- 5 The plate may contain more than one depression, each depression being of the size and shape corresponding to the desired size of the shaped article. However the mold may also be a depression in a sheet of filmic material. The filmic material may contain more than one depression. The filmic material may be similar to that employed in conventional blister packs which are used for packaging pharmaceutical tablets and like
- 10 medicament forms. For example, the filmic material may be made of thermoplastic material with the depressions formed by thermo-forming. The preferred filmic material is a talc-filled polypropylene film or a polyvinyl chloride film. Laminates of filmic material such as polyvinyl chloride/polyvinylidene chloride, polyvinyl chloride / poly-tetrafluorethylene or polyvinyl chloride / polyvinylidene chloride/polyethylene may
- 15 also be used.

- Where lyophilization is used, it may be advantageous to freeze the matrix material solution in molds that are coated or lined for easy release of the frozen material. Preferred molds are thermoformed cups made in talc-filled polypropylene sheets,
- 20 optionally siliconized with a layer of silicone/simethicone baked on the surface(s) which come into contact with the aqueous composition.

- Dosage forms may be prepared in a wide variety of sizes, ranging from about 0.25 ml or g to 30 ml or g and larger. Large dosage forms may be advantageously prepared by
- 25 the solid state dissolution process without the long drying times required by lyophilization. The frozen and desolvated dosage forms may be of a size corresponding to the desired size of two or more dosage forms. For example, the composition may be frozen in a tray and the solvent removed from the frozen composition to produce a slab or a sheet of desolvated product corresponding in size to that of a number of the desired
- 30 shaped articles. The sheet may be subdivided to form products of the desired size and the active ingredient may be post-loaded on to the subdivided products by injecting a predetermined amount of a suspension comprising said active ingredient. A particular advantage of this alternative resides in the fact that the subdivision of the sheet does not need to be carried out accurately since a measured amount of active ingredient is added
- 35 to the subdivided products. In addition, if the injected suspension does not diffuse excessively through the sheet of sublimed product, the sheet may be dosed with the predetermined amount of active ingredient at selected positions on the sheet prior to

subdivision and the sheet subsequently subdivided to give dosage forms each containing the predetermined amount of active ingredient.

5 The present invention also provides marked, solid rapidly disintegrating dosage forms obtainable by any one of the processes described hereinbefore.

10 The speed with which the marked tablet prepared by the inventive method disintegrates is dependent entirely or at least in large part on the choice of matrix forming agent(s), their concentration and the solidification/desolvation process conditions. In particular, dosage forms of the size mentioned in the examples described hereinafter, will dissolve or disperse rapidly, for example, in less than about 10 seconds and generally faster e.g. in less than about 5 seconds or even less, e.g. within 1 to 2 seconds.

15 The dosage forms disperse rapidly in water, e.g. in less than 10 seconds. The disintegration time of a dosage form is determined to check whether it is capable of being disintegrated by water sufficiently rapidly using a standard tablet disintegration apparatus as described in British Pharmacopoeia, 1980, Vol II, Appendix XII A, but with the standard 2.00 mm wire mesh replaced by stainless steel 40 mesh screen. A sample product is placed in a dry tube held above the surface of the water. The
20 apparatus is started and the sample immersed in water at 20°C. The sample should disperse on the liquid surface and any solid residue should pass through the 40 mesh screen within 10 seconds, preferably within 5 seconds and ideally within 1 to 2 seconds.

Claims

1. A method of marking the surface of solid rapidly disintegrating dosage forms comprising a non-compressed, porous network of matrix forming materials,
5 characterized in that legible marks and / or characters are applied to the surface of said solid rapidly disintegrating dosage forms using non-contact marking techniques.
2. A method according to claim 1 wherein the non-contact marking techniques
10 comprise laser imprinting and ink-jet printing.
3. A method according to claim 2 wherein a laser is used to etch marks and / or characters into the surface of the dosage form by vaporizing a shallow and narrow
15 portion of the surface.
4. A method according to claim 3 wherein the marks and / or characters are etched into the surface of the dosage form by passing the laser beam through a precut mask or stencil.
- 20 5. A method according to claim 3 wherein the marks and / or characters are etched into the surface of the dosage form by moving the dosage form past a plurality of pulsed laser beams arranged along a single line, thus creating dot matrix patterns on the surface.
- 25 6. A method according to claim 3 wherein the marks and / or characters are etched into the surface of the dosage form by scanning a laser beam over the surface of the dosage form using rapidly rotating, computer controlled mirrors.
7. A method according to claim 2 wherein an ink-jet printer is used to print marks and
30 / or characters onto the surface of the dosage form by dotting droplets of an ink onto said surface.
8. A method according to claim 7 wherein the ink is suspended or dissolved in a
35 liquid, volatile carrier.

9. A method according to claim 8 wherein the dosage form is marked by means of an ink-jet printer dotting droplets of a pharmaceutically acceptable, edible ink onto the surface of the dosage form.
- 5 10. A method according to claim 1 wherein the dosage form is loaded with a predetermined amount of an active ingredient and is shaped as a tablet.
11. A method according to claim 10 wherein the active ingredient is a drug substance for human or veterinary use and the solid rapidly disintegrating dosage form is a
10 pharmaceutical tablet for oral administration.
12. A method according to claim 1 wherein the matrix forming material comprises
i) a water-soluble, hydratable gel or foam-forming material,
ii) a rigidifying agent for the gel or foam-forming material, and optionally
15 iii) one or more amino acids.
13. A method according to claim 12 wherein the gel or foam-forming material is a proteinaceous materials such as gelatin, gelatin A, gelatin B, fluid gelatin, modified
20 fluid gelatin, gelatin derivatives, albumin, soy fiber protein, wheat and psyllium seed proteins, potato protein, papain ; phospholipids such as coacervate egg lecithin, or lecithin; gums such as acacia, guar, agar, locust bean, xanthan and tragacanth gum ; polysaccharides such as alginates (polymannuronic acid), chitosan, carrageenans, dextrans, dextrins, maltrins (maltodextrins), pectins (polygalact-uronic acid), microcrystalline cellulose, corn syrup solids, konjac flour,
25 rice flour, wheat gluten ; synthetic polymers such as polyvinylpyrrolidone, sodium carboxymethyl-cellulose, sodium starch glycolate, hydroxyethylcellulose; and polypeptide/protein or polysaccharide complexes such as gelatin-acacia complexes, each singly or in combination.
- 30 14. A method according to claim 12 wherein the rigidifying material is a monosaccharide, a linear or cyclic oligosaccharide, a polysaccharide, or an inorganic substance, or a combination thereof.
- 35 15. A method according to claim 14 wherein the rigidifying material is mannitol, xylitol, sorbitol, dextrose, fructose, sucrose, lactose, maltose, galactose, trehalose ; a cyclic sugar such as beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin, dextran, dextrin, an inorganic substance such as sodium phosphate, sodium

chloride, a magnesium aluminum silicate, magnesium trisilicate, a natural clay, or a combination thereof.

- 5 16. A method according to claim 12 wherein the amino acid is glycine, L-aspartic acid, L-glutamic acid, L-hydroxyproline, L-isoleucine, L-phenylalanine, or a combination thereof.
- 10 17. A method according to claim 12 wherein the matrix forming materials further comprise nutrients, vitamins, other active ingredients, sweeteners, flavouring agents, colouring agents, surfactants, preservatives, antioxidants, viscosity enhancers, minerals, diagnostics, fertilizers or insecticides.
- 15 18. A solid rapidly disintegrating dosage form with legible marks and / or characters obtainable by any one of the methods of claims 1 to 17.
19. A dosage form according to claim 18 which disintegrates within 10 seconds in water at 20°C.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 9/20	A3	(11) International Publication Number: WO 97/48384 (43) International Publication Date: 24 December 1997 (24.12.97)
(21) International Application Number: PCT/EP97/03066 (22) International Filing Date: 10 June 1997 (10.06.97) (30) Priority Data: 60/020,274 17 June 1996 (17.06.96) US (60) Parent Application or Grant (63) Related by Continuation US 60/020,274 (CON) Filed on 17 June 1996 (17.06.96) (71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B- 2340 Beerse (BE). (72) Inventor; and (75) Inventor/Applicant (for US only): POSAGE, Gary, W. [US/US]; Janssen Research Technology Center, 655 Phoenix Drive, Ann Arbor, MI 48108 (US).		(81) Designated States: AL, AM, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 5 February 1998 (05.02.98)
(54) Title: MARKING RAPIDLY DISINTEGRATING DOSAGE FORMS (57) Abstract The present invention relates to a method of marking the surface of solid rapidly disintegrating dosage forms using a non-contact marking technique such as laser imprinting and ink-jet printing.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

Int'l. Application No

PCT/EP 97/03066

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K9/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 09608 A (SCHERER CORP R P ; THOMPSON ANDREW R (GB); YARWOOD RICHARD J (GB);) 13 April 1995 see page 1, line 4 - line 7 see page 3, line 24 - page 4, line 2 see claim 3 ---	1-19
Y	WO 93 23017 A (JANSSEN PHARMACEUTICA INC) 25 November 1993 cited in the application see the whole document ---	1-19
Y	CH 660 750 A (THOMAE GMBH DR K; BUETTNER AG FRANZ) 15 June 1987 see page 2, column 2, line 27 - line 37 see page 3, column 1, line 28 - line 31 see page 4: example 3 --- -/--	1,7-19



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "3" document member of the same patent family

Date of the actual completion of the international search

19 November 1997

Date of mailing of the international search report

03/12/1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040. Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Boulois, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/03066

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 548 825 A (VOSS GUENTHER ET AL) 22 October 1985 see column 1, line 54 - line 64 see column 7; example 1 ---	1,7-19
Y	PATENT ABSTRACTS OF JAPAN vol. 016, no. 380 (M-1295), 14 August 1992 & JP 04 122688 A (TAKEDA CHEM IND LTD), 23 April 1992, see abstract ---	1-6, 10-19
Y	PATENT ABSTRACTS OF JAPAN vol. 010, no. 151 (M-483), 31 May 1986 & JP 61 005988 A (TOSHIBA KK), 11 January 1986, see abstract -----	1-6, 10-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/03066

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9509608 A	13-04-95	US 5457895 A AU 7801494 A EP 0721325 A JP 9506268 T	17-10-95 01-05-95 17-07-96 24-06-97
WO 9323017 A	25-11-93	AU 677198 B AU 4232293 A BG 99158 A CA 2135062 A CN 1085081 A CZ 9402654 A EP 0642334 A FI 945198 A HU 68224 A HU 9500465 A JP 7508019 T NO 944207 A NZ 252526 A PL 172354 B SK 132094 A US 5558880 A US 5648093 A	17-04-97 13-12-93 31-05-95 25-11-93 13-04-94 15-02-95 15-03-95 04-11-94 28-06-95 28-12-95 07-09-95 04-11-94 26-09-95 30-09-97 11-07-95 24-09-96 15-07-97
CH 660750 A	15-06-87	NONE	
US 4548825 A	22-10-85	DE 2849494 A AT 2113 T AU 530180 B AU 5285779 A CA 1144479 A CS 222678 B DD 147203 A EP 0011268 A JP 1639610 C JP 2048524 B JP 55108815 A SU 1017160 A US 4322449 A US RE31764 E	29-05-80 15-01-83 07-07-83 22-05-80 12-04-83 29-07-83 25-03-81 28-05-80 18-02-92 25-10-90 21-08-80 07-05-83 30-03-82 11-12-84